Every Form 4 that Equillium, Inc. (EQ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EQ filings page.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sale transaction in company stock. She exercised employee stock options to acquire 14,584 shares of common stock at an exercise price of $0.7850 per share, then sold 14,584 shares in an open-market transaction at a weighted average price of $2.9304 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2025, indicating it was scheduled in advance. After these transactions, she holds 62,586 shares of common stock directly and 25,521 stock options that remain outstanding and unexercised.
Equillium, Inc. President and CSO Stephen Connelly reported open-market sales of company common stock. He sold 200,000 shares on June 4, 2026 at a weighted average price of $3.1638 per share, in multiple trades between $3.07 and $3.345.
On June 5, 2026, he sold an additional 30,975 shares at a weighted average price of $2.9401, in trades between $2.83 and $3.06. After these transactions, he directly holds 762,025 shares of Equillium common stock.
Equillium, Inc. Principal Accounting Officer Tom Penny exercised options and sold shares in a coordinated transaction. He exercised an employee stock option to acquire 65,000 shares of Common Stock at $0.785 per share, then sold 65,000 shares in an open-market transaction at a weighted average price of $2.95 per share, with individual sale prices ranging from $2.95 to $2.99. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2025, indicating they were scheduled in advance. Following these transactions, Penny reported owning no shares of Common Stock and the corresponding option for 65,000 shares was fully exercised with no remaining balance.
Equillium, Inc. director Martha J. Demski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and were awarded as compensation, not purchased in the open market.
The option vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested by the company’s next annual meeting of stockholders following the grant date. Following this grant, Demski holds derivative rights over 70,000 shares through this option award.
Equillium, Inc. director Mark Pruzanski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.8400 per share and bring his directly held option position reported in this filing to 70,000 derivative securities.
According to the terms, the option vests in twelve equal monthly installments starting on the grant date of May 28, 2026, and will in any case be fully vested on the date of Equillium's annual meeting of stockholders following that grant date. The option expires on May 27, 2036.
Equillium, Inc. disclosed that chairman and director Daniel Bradbury received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments beginning on May 28, 2026, and will in any case be fully vested on the date of Equillium’s next annual meeting of stockholders following the grant date. This is a compensation-related equity grant, not an open-market share purchase or sale.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported a set of option exercises paired with open-market sales of common stock. She exercised employee stock options to acquire 95,833 shares at strike prices between $0.73 and $0.785 per share, then sold 95,833 shares at market prices around the high $2 range. After these transactions, she directly holds 62,586 shares of Equillium common stock. A footnote states that at least part of the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.
Equillium, Inc. director Charles Douglas McDermott received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested on the date of Equillium's next annual meeting of stockholders following the grant date. Following this grant, McDermott holds 70,000 derivative securities directly.
Equillium, Inc. director Barbara Troupin received a grant of options to purchase 70,000 shares of common stock at an exercise price of $2.84 per share. These director stock options vest in twelve equal monthly installments starting on May 28, 2026 and will be fully vested no later than the issuer's next annual stockholder meeting following the grant date. After this grant, Troupin holds 70,000 derivative securities directly.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised options to acquire 120,312 shares of common stock at an exercise price of $0.785 per share. She then sold 120,312 shares of common stock at a weighted average price of $2.5003 per share in open-market transactions effected under a Rule 10b5-1 trading plan adopted on August 27, 2025. Following these transactions, she directly holds 62,586 shares of Equillium common stock. The option exercised had been scheduled to vest over four years, with 25% on the first anniversary and the remainder in 36 equal monthly installments.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sell set of transactions in company common stock. On February 19, 2026, she exercised options to acquire a total of 185,937 shares of common stock at prices of $0.785 and $0.73 per share.
On the same date, she sold the same 185,937 shares in open-market transactions at average prices of about $1.78 per share. After these trades, she directly held 91,444 shares of Equillium common stock. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025, indicating they were pre-arranged rather than timed discretionarily.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.
The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.
Equillium, Inc. executive Christine Zedelmayer reported option exercises and related share sales in a Form 4. On February 19, 2026, she exercised employee stock options covering 109,375 and 76,562 shares, converting them into common stock at stated exercise prices.
On the same date, she sold 109,375 shares at $1.7814 per share and 76,562 shares at $1.7406 per share in open-market transactions. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions, she directly owned 191,444 shares of Equillium common stock.
Equillium, Inc. granted its President and Chief Scientific Officer, Stephen Connelly, an employee stock option to buy 1,150,000 shares of common stock at an exercise price of $1.31 per share on 01/07/2026. The option has an expiration date of 01/06/2036 and was received at no cost, as reflected by a derivative security price of $0.
According to the vesting terms, 25% of the shares under the option vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Connelly beneficially holds 1,150,000 stock options directly.
Equillium, Inc. reported that Sr. Vice President and COO Christine Zedelmayer received an employee stock option grant on 01/07/2026. The derivative award covers 500,000 stock options with an exercise price of $1.31 per share, allowing her to buy common stock at that price in the future. The grant was reported at a cost of $0 for the option itself and leaves her with 500,000 derivative securities beneficially owned directly after the transaction.
According to the vesting terms, 25% of the option vests on the first anniversary of the vesting commencement date, and the remaining options vest in 36 equal monthly installments over the following three years, resulting in a standard four-year vesting schedule tied to ongoing service.
Equillium, Inc. reported that its Chief Executive Officer, director and 10% owner, Bruce D. Steel, was granted an employee stock option on 01/07/2026. The option covers 1,750,000 shares of common stock at an exercise price of $1.31 per share and expires on 01/06/2036. According to the vesting terms, 25% of the shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Steel beneficially holds 1,750,000 derivative securities directly.
Equillium, Inc. Principal Accounting Officer Tom Penny reported one stock sale and a new stock option grant. Penny sold 6,533 shares of common stock on January 8, 2026 at $1.29 per share, leaving him with no shares of common stock held directly after the sale. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on October 10, 2025, meaning they were pre‑scheduled rather than discretionary.
On January 7, 2026, Penny was granted an employee stock option to purchase 450,000 shares of Equillium common stock at an exercise price of $1.31 per share. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, he holds 450,000 stock options directly.
Equillium’s Senior Vice President and Chief Operating Officer reported open-market sales of company common stock. On December 12, 2025, the executive sold 23,804 shares of Equillium common stock at a price of $1.34 per share. On December 15, 2025, an additional 11,900 shares were sold at $1.31 per share.
Following these transactions, the reporting person beneficially owned 91,444 shares of Equillium common stock in direct ownership. The filing notes that the reported sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is a pre-arranged plan for trading company stock.
Equillium, Inc. (EQ) reported an insider stock sale by its Sr. Vice President and COO on a Form 4. On 11/25/2025, the officer sold 100 shares of common stock at $0.98 per share and another 7,998 shares at $0.95 per share. After these transactions, the officer beneficially owned 127,148 shares of Equillium common stock directly. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.